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Abstract
Introduction: The aim of the study was to evaluate the effects of high-dose fenoldopam, a selective dopamine-1
receptor, on renal function and organ perfusion during cardiopulmonary bypass (CPB) in infants with congenital
heart disease (CHD).
Methods: A prospective single-center randomized double-blind controlled trial was conducted in a pediatric
cardiac surgery department. We randomized infants younger than 1 year with CHD and biventricular anatomy
(with exclusion of isolated ventricular and atrial septal defect) to receive blindly a continuous infusion of
fenoldopam at 1 μg/kg/min or placebo during CPB. Perioperative urinary and plasma levels of neutrophil
gelatinase-associated lipocaline (NGAL), cystatin C (CysC), and creatinine were measured to assess renal injury
after CPB.
Results: We enrolled 80 patients: 40 received fenoldopam (group F) during CPB, and 40 received placebo (group
P). A significant increase of urinary NGAL and CysC levels from baseline to intensive care unit (ICU) admission
followed by restoration of normal values after 12 hours was observed in both groups. However, urinary NGAL and
CysC values were significantly reduced at the end of surgery and 12 hours after ICU admission (uNGAL only) in
group F compared with group P (P = 0.025 and 0.039, respectively). Plasma NGAL and CysC tended to increase
from baseline to ICU admission in both groups, but they were not significantly different between the two groups.
No differences were observed on urinary and plasma creatinine levels and on urine output between the two
groups. Acute kidney injury (AKI) incidence in the postoperative period, as indicated by pRIFLE classification
(pediatric score indicating Risk, Injury, Failure, Loss of function, and End-stage kidney disease level of renal damage)
was 50% in group F and 72% in group P (P = 0.08; odds ratio (OR), 0.38; 95% confidence interval (CI), 0.14 to 1.02).
A significant reduction in diuretics (furosemide) and vasodilators (phentolamine) administration was observed in
group F (P = 0.0085; OR, 0.22; 95% CI, 0.07 to 0.7).
Conclusions: The treatment with high-dose fenoldopam during CPB in pediatric patients undergoing cardiac
surgery for CHD with biventricular anatomy significantly decreased urinary levels of NGAL and CysC and reduced
the use of diuretics and vasodilators during CPB.
Trial registration: Clinical Trial.Gov NCT00982527.
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Cardiopulmonary bypass (CPB) represents a unique clin-
ical circumstance in which nearly all aspects of perfu-
sion can be determined by clinicians. So far,
considerable controversy relates to appropriate manage-
ment of physiologic variables during pediatric CPB (per-
fusion pressure, bypass flow rates, type of flow (pulsatile
versus nonpulsatile), hematocrit values, systemic oxygen
delivery (DO2), temperature, and acid-base manage-
ment), resulting in significant differences in how bypass
is conducted in cardiac centers [1,2]. In light of this,
pathogenesis of CPB-associated renal dysfunction has
not been fully elucidated [3,4], and no proven effective
prophylaxis or treatment has been established. Acute
kidney injury (AKI) after cardiac operations with CPB is
a life-threatening complication, with a reported inci-
dence of up to 36% [5]. When dialytic treatment is
required, the mortality rate may reach 50% [6,7]. Var-
ious factors related to the CPB procedure have been
advocated as possible determinants of AKI. They include
CPB duration, red blood cell fragmentation and hemoly-
sis, sublethal red cell damage, resulting in altered rheo-
logic properties, a low perfusion pressure, low pump
flow, severe hemodilution, and low DO2[8-10]. In chil-
dren, after CPB, the combined effects of hypothermia,
nonpulsatile perfusion, and reduced mean arterial pres-
sure are involved in the release of angiotensin, renin,
catecholamines, and antidiuretic hormone. These circu-
lating substances promote renal vasoconstriction and
reduce renal blood flow [11]. Furthermore, the glomeru-
lar filtration rate, creatinine clearance, and medullary
concentrating capacity are substantially reduced in neo-
nates and young infants, with a net result of increased
total body water, increased organ weight (for example,
lungs, heart), and greater difficulty with postoperative
weaning from ventilatory support [11].
Creatinine, urea nitrogen levels, or urine output are
only very late markers for the diagnosis of AKI [12,13].
Neutrophil gelatinase-associated lipocalin (NGAL) and
cystatin C (CysC) have been recently suggested to be
early AKI biomarkers in both adult and pediatric
cardiac surgery [14-17]. Different pharmacologic
approaches have been experimented with to optimize
organ perfusion during CPB. In particular, phentola-
mine [18], phenoxybenzamine [19], and sodium nitro-
prusside [20] have been used, because of their
vasodilative properties, to manage hypoxic vasocon-
striction on CPB, with conflicting results. These agents
have rarely been tested with clinical biomarkers of kid-
ney function [21]; typically, diuretics have been the
mainstay of promoting renal function and urine flow
after pediatric CPB [22,23]. Fenoldopam mesylate is a
short-acting dopamine-1 (DA-1) agonist with antihy-
pertensive and vasodilative properties [24] that has
been used during adult cardiac surgery with conflicting
results [25,26]. It appears to improve renal function in
clinical situations of reduced blood flow by increasing
renal blood flow to both the cortex and medullary
regions [24]. In pediatric critically ill patients and
pediatric cardiac surgery, fenoldopam has been pro-
posed as a nephroprotective agent with additional
diuretic properties [27,28]. In light of this, fenoldopam
would appear to be the optimal drug during pediatric
CPB, to optimize organ perfusion by systemic vasodila-
tion with a potential specific benefit on renal function.
Its commonly used clinical dosage ranges from 0.1 to
0.3 μg/kg/min [29,30]. Recently, this agent has been
evaluated for controlled hypotension during pediatric
abdominal surgery, and the dosage range has been
reported effective between 0.8 and 1.2 μg/kg/min.
Doses greater than 1.2 μg/kg/min resulted in increas-
ing heart rate without additional reduction in blood
pressure [31].
The present study aimed to evaluate the effects of
high-dose fenoldopam infusion (1 μg/kg/min) on pro-
tecting the kidney from CPB-associated AKI, by perio-
perative measurements of urinary and plasma NGAL
and CysC levels in infants with CHD.
Materials and methods
Study design
A single-center prospective double-blind randomized
placebo-controlled trial was performed at a tertiary
pediatric hospital. The study was approved by the local
Ethics Committee ("Comitato Etico per la Sperimenta-
zione Clinica"; approval number, 250) and was registered
in the Protocol Registration System (Clinical Trial. Gov
Id: NCT00982527).
Objectives
The primary end point of this study was to assess
whether high-dose fenoldopam infusion during CPB
affects renal function by perioperative urinary and
plasma NGAL, CysC, and Crea levels measurement. Sec-
ondary outcomes were the evaluation of postoperative
AKI incidence, as indicated by pRIFLE (pediatric score
indicating Risk, Injury, Failure, Loss of function, and
End-stage kidney disease level of renal damage) classifi-
cation [32]; high-dose fenoldopam infusion efficacy was
assessed by CPB perfusion features in the two groups
(see later) and by the requirement of diuretics and vaso-
dilators during the CPB period. Finally, the number of
times that the vasodilator infusion was halted because of
hypotension (or other side effects) was recorded as a
measure of fenoldopam safety.
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Inclusion criteria were age younger than 1 year, need for
cardiac surgery, and CPB for correction of CHD with
biventricular anatomy. Exclusion criteria were surgery
for simple ventricular septal defect and atrial septal
defect, the presence of preoperative renal dysfunction,
predetermined need for deep hypothermic circulatory
arrest (DHCA), urgent procedures, and the absence of
informed consent. The study was conducted between
July 2009 and July 2010.
Randomization procedure
The allocation sequence was generated by using two
computerized random-generation programs stratified by
two age groups: (a) neonates (surgery before 30 days
after birth) and (b) infants (surgery between 31 and 365
days after birth). To recruit the same proportion of
cases, the number of enrolled neonates was limited to
13 per group (32%), reflecting the institutional rate of
neonatal surgery. The patients were evaluated for elig-
ibility the day before surgery, and informed consent was
obtained from both parents. After recruitment, the day
of operation, sealed envelopes containing the allocation
g r o u pw e r eo p e n e db yan u r s ew h od i dn o tp a r t i c i p a t e
in the study or in data collection. The same nurse was
in charge of preparing the infusions that were blindly
given to the perfusionist. The rest of the nurses and
medical staff in the operation room and in the intensive
care unit were blinded to group assignment.
Interventions
All patients received general anesthesia with sevorane
inhalation at induction and then midazolam (0.05 mg/
kg/h), fentanyl (5 μg/kg/h), and cisatracurium (0.08 mg/
kg/h) infusion for maintenance. CPB was always con-
ducted with open circuits, alpha stat strategy, and blood
cardioplegia, targeting CPB flow to 150 ml/kg/min,
hematocrit to 35%, and moderate hypothermia with the
temperature ranging between 25°C and 32°C. During
CPB, boluses of phentolamine (0.1 μg/kg) were adminis-
tered when perfusion pressure at full perfusion flow
increased over 50 mm Hg. Patients were blindly allo-
cated to the study group (group F) or to placebo (group
P) after anesthesia induction. A continuous infusion of
f e n o l d o p a ma tt h ed o s eo f1μg/kg/min was adminis-
tered from CPB start to CPB weaning. The drug was
always prepared in 25 ml of saline and infused at a rate
of 1 ml/h. Group P received a saline solution, infused at
the same rate as that of fenoldopam. Infusion was admi-
nistered directly into the CPB reservoir. No changes to
the intraoperative standard of care were applied during
the study period: in particular, fluid balance was con-
trolled by conventional ultrafiltration before CPB wean-
ing (about 50 ml/kg of ultrafiltered volume) and by
furosemide administration (1 mg/kg) if the urine output
before CPB weaning was less than 1 ml/kg/h. The
attending anesthesiologist was authorized to interrupt
drug infusion due to suspicion of side effects such as
excessive hypotension, arrhythmias, or intolerance.
Data collection
Demographic and baseline characteristics of included
patients were collected after enrolment. Urinary output,
plasma and urinary levels of creatinine (respectively,
pCrea and uCrea), NGAL (respectively, pNGAL and
uNGAL), and CysC (respectively, pCysC and uCysC),
blood lactates concentration, superior vena cava oxygen
saturation (ScvO2) and cerebral near-infrared spectro-
scopy (rSO2c) value were measured before surgery (t0),
at the end of the surgical procedure (t1), and 12 hours
after ICU admission (t2). Creatinine levels and urinary
output were recorded in the first 96 postoperative days
to compute pRIFLE classification.
PCrea and uCrea levels were directly sent to the
laboratory and measured with the Jaffe assay (ADVIA
Chemistry Systems, Siemens, Munich, Germany). Urine
samples for uNGAL and uCysC were collected in dedi-
cated sterile vials, centrifuged at 2,000 rpm, and the
supernatant immediately stored at -80°C. Blood samples
for pNGAL and pCysC were collected in sterile vials
containing heparin as an anticoagulant, centrifuged at
3,600 rpm, and the supernatant immediately stored at
-80°C. Plasma and urinary NGAL were measured with a
sandwich enzyme-linked immunosorbent assay (R&D
Systems, Minneapolis, MN, U.S.A.), whereas plasma and
urinary cystatin C were evaluated with nephelometry
(BN ProSpec; Siemens).
All CPB data (pump flow, minimum temperature,
hematocrit, perfusion pressure, furosemide boluses,
phentolamine boluses, hemofiltration volume) were pro-
spectively collected by perfusionists, and the average
values per each CPB session of every patient were
recorded. Average indexed DO2 and systemic vascular
resistances (SVRs) were calculated for each patient dur-
ing CPB. DO2 was calculated as follows: CPB pump flow
× arterial oxygen content (assumed as hemoglobin con-
centration × hemoglobin saturation × 1.34 + 0.003 ×
arterial oxygen tension). SVRs were calculated as fol-
lows: 80 × (CPB pressure-central venous pressure)/CPB
pump flow. At ICU admission and after 24 hours, in the
absence of other direct instrumental measures of cardiac
performance, the hemodynamics was evaluated with the
mean arterial pressure (MAP) and inotropic score (IS)
that indicates different inotropic and vasopressor drug
regimens, reflecting dosage of vasoconstrictors/inotropic
drugs. IS was calculated as [33]: dopamine μg/kg/min ×
1 + dobutamine μg/kg/min × 1 + milrinone μg/kg/min
× 15 + epinephrine μg/kg/min × 100. Survival, length of
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recorded. Risk-adjusted classification for congenital
heart surgery (RACHS-I) was used to compare the
severity of surgical risk in the populations [34]. All data
were recorded on an Access-based database specifically
prepared for this study.
Statistical analysis
Intention to treat (ITT) was applied, and all enrolled
patients were considered for statistical analysis at the
end of the study. The c
2 test was used to compare cate-
goric variables. To compare continuous variables, a
Mann-Whitney test or Student t test was used, accord-
ing to the variable distribution. Two-way analysis of var-
iance was used to compare continuous variables over
time between the two groups, with the Bonferroni post
hoc test for each time point. All data are presented as
mean and standard deviation (SD). A P value < 0.05 was
considered significant. Statistical analysis was performed
with the GraphPad Prism 5.0 software package (Graph-
Pad Software, San Diego, CA, U.S.A.).
The study was powered on the primary outcome
based on a previous landmark study [15]: considering a
mean (SD) of uNGAL level, 2 hours after CPB weaning,
of 150 (90) ng/ml, and a 50 ng/ml uNGAL difference
between the two groups, to achieve an 80% statistical
p o w e rw i t ha na l p h ae r r o ro f0 . 0 5 ;t h en u m b e ro f
patients was calculated to be 40 for each group. An
interim analysis was planned after enrolment of 40
patients, and a stopping rule was determined in case of
major morbidity detected in this phase.
Results
Figure 1 depicts the flow chart of enrolment phases: in
only one case was treatment interrupted by mistake
(group P), but data from this patient were analyzed with
ITT. Tables 1 and 2 describe baseline characteristics of
the two groups that showed similar clinical
characteristics.
Primary end points
In both groups, a significant increase of urinary NGAL
and CysC levels and a consequent decrease of uCrea
was observed from baseline to t1 (P = 0.003, 0.03, and
0.0001, respectively), followed by a trend to restoration
of normal biomarkers values (Table 3). Considering an
average CPB length of 200 minutes and an average total
surgery time of 400 minutes in both groups (Table 1), it
can be estimated that the t1 NGAL measurement was
done in all patients about 150 minutes after CPB stop.
However, uNGAL values were significantly reduced at
t1 and t2 in group F with respect to group P (Figure 2)
(P = 0.025); furthermore, if a uNGAL cut-off value of
200 ng/ml was chosen, as previously suggested [35], this
value was reached in significantly more children in
g r o u pP( 2 8 % )w i t hr e s p e c tt og r o u pF( 5 % )( P = 0.024;
OR, 0.15; CI, 0.03 to 0.75). UCysC values were signifi-
c a n t l yr e d u c e da tt 1i ng r o u pFw i t hr e s p e c tt og r o u pP
(Figure 3) (P = 0.039); no differences were observed in
uCrea levels between the two groups (Table 3). Plasma
biomarkers levels (pNGAL, pCysC, and pCrea) signifi-
cantly increased from t0 to t1 in both groups (P=
0.0001 for all biomarkers). PNGAL, pCys, and pCrea
values were not significantly different between the two
groups (Table 3).
 
Assessed for 
 eligibility:  100 
Excluded 20: 
-Did not meet inclusion criteria: 
18 
- Refused consent: 2 
Randomized: 80 
Allocated to fenoldopam: 40 
Received allocated 
intervention: 40 
None lost to follow up 
No discontinued 
intervention 
Analyzed 40 
None excluded from the 
analysis 
Allocated to placebo: 40 
Received allocated 
intervention: 40 
None lost to follow up 
1 discontinued intervention 
(infusion stopped by the 
anaesthesiologist) 
Analyzed 40 
None excluded from 
the analysis 
Figure 1 Flow chart of enrolment phases.
Table 1 Demographic characteristics of enrolled patients
and main cardiopulmonary bypass (CPB) features
Group F Group P P
Age (days) 145 (156) 139 (130) 0.791
Weight (kg) 5.1 (2.0) 5.0 (2.2) 0.652
BSA (m
2) 0.5 (0.2) 0.5 (0.3) 0.698
RACHS II score 2.7 (0.6) 2.6 (0.6) 0.366
Surgical procedure (minutes) 390 (84) 401 (82) 0.599
CPB (minutes) 212 (70) 217 (74) 0.905
Crossclamp (minutes) 119 (44) 118 (41) 0.923
Prescribed CPB flow (ml/kg/min) 150 (0) 150 (0) 0.90
Ht during CPB (%) 32 (1.9) 33 (2.1) 0.237
T min during CPB (°) 27.1 (2.5) 27.8 (1.9) 0.418
BSA, body surface area; Ht, hematocrit; RACHS II, risk adjustment for
congenital heart surgery; T, central body temperature. Data are expressed as
mean (standard deviation).
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AKI incidence, as indicated by pRIFLE classification, was
50% in group F and 72% in group P (P = 0.08, OR, 0.38;
95% CI, 0.14 to 1.02). AKI patients were classified in
90% of cases in the “Risk” level of severity in both
groups, with four “Injury” cases in group F and five in
group P. Intra- and postoperative urine output was simi-
lar in the two groups (Table 4). Only one patient in
group P required postoperative peritoneal dialysis. Aver-
age perfusion pressure was 47.16 (4.72) mm Hg in
group F and 49.08 (4.61) mm Hg in group P (P =
0.048), whereas CPB average effective flow rate was 151
(12.5) ml/kg/min in group F and 146.5 (16) ml/kg/min
in group P (P = 0.142) (Table 4). ScvO2,r S O 2c, blood
lactates, mean indexed SVR, and mean indexed DO2
values were not different between groups during the
CPB phase (Table 4); however, we observed a signifi-
cantly higher number of patients with a DO2 lower than
272 ml/min/mq (8% vs. 27%; P = 0.048; OR, 0.27; 95%
C I ,0 . 0 6t o0 . 9 )i nt h eFg r o u p ,aD O 2 value recently
described as the cut-off level below which risk of AKI
occurrence is potentially increased [10]. The number of
patients that did not receive any phentolamine and/or
furosemide boluses during CPB to target CPB perfusion
pressure or urine flow was significantly higher in group
F (58%) versus group P (9%) (P = 0.0085; OR, 0.22; 95%
CI, 0.07 to 0.7). IS did not show significant differences
among the two groups either at CPB weaning or in the
postoperative phase (Table 4). No side effects were
reported in any case of group F. Patients in group F
were extubated after 3.8 (3.2) days versus 4.4 (3.7) days
for patients in group P (P =0 . 0 6 ) .L e n g t ho fs t a yw a s
5.8 (4.8) days in group F versus 7 (5.3) days in group P
(P = 0.055). All patients survived to hospital discharge.
Discussion
Evaluation of organ perfusion and protection during
CPB, the gold standard of any CPB procedure, may
depend on how carefully organ function is assessed. In
light of this, sensitive and specific biomarkers of
ischemic kidney injury might be extremely useful in
Table 2 Number of neonates and diagnoses of enrolled
patients
Diagnoses Group F Group P
Number of neonates/total number of patients 13/40 13/40
PA + VSD 2 1
PA + VDS + MAPCAS 2 2
CAVc 5 5
Aortic coarctation and VSD 2 2
ASD-VSD 2 2
Ao supravalvar stenosis 2 2
TOF 12 14
TGA and VSD 2 1
IS-TGA 9 9
TA 2 2
Total 40 40
Ao, aortic; ASD, atrial septal defect; IS, intact septum; MAPCAS, multiple
aortopulmonary collaterals; PA, pulmonary atresia; TA, truncus arteriosus; TGA,
transposition of the great arteries; TOF, tetralogy of Fallot; VSD, ventricular
septal defect.
Table 3 Renal biomarkers levels in fenoldopam group (F) and placebo group (P) before surgery (t0), at the end of
surgical procedure (t1), and 12 hours after intensive care unit admission (t2)
T0 T1 T2 P
Group F Group P Group F Group P Group F Group P
uNGAL (ng/ml) 37.2 (84.5) 37 (232) 94.2 (240)
a 140 (249) 20.4 (15.7)
a 57 (105) 0.025
pNGAL (ng/ml) 62 (33) 66 (31) 88 (38) 96 (40) 93 (45) 99 (41) 0.253
uCys C (mg/l) 0.12 (0.2) 0.08 (0.06) 0.16 (0.3)
a 0.22 (0.5) 0.06 (0.04) 0.09 (0.13) 0.039
pCys C (mg/l) 1.0 (0.3) 1.1 (0.3) 0.96 (0.28) 1.0 (0.25) 1.19 (0.3) 1.3 (0.3) 0.344
pCrea (mg/dl) 0.51 (0.15) 0.46 (0.16) 0.63 (0.17) 0.64 (0.13) 0.64 (0.2) 0.62 (0.2) 0.114
uCrea (mg/dl) 53.5 (37.4) 49.6 (33.7) 8.5 (5.5) 8.5 (7.6) 26.4 (23.4) 26.4 (23.7) 0.707
Mean (standard deviation) levels of plasma and urinary levels of creatinine (respectively, pCrea and uCrea), neutrophil gelatinase-associated lipocalin (respectively,
pNGAL and uNGAL), and cystatine-C (respectively, pCysC and uCysC) are reported.
aSignificant differences by Bonferroni post test of ANOVA. We found a
significant difference between groups of uNGAL levels at t1 (P=0.02) and t2 (P=0.04) and of uCysC levels at t1 (P=0.04). Data are expressed as mean
(standard deviation).
Figure 2 Urinary neutrophil gelatinase-associated lipocaline
(uNGAL) levels. A significant increase of uNGAL levels from
baseline (t0) to ICU admission (t1) and a consequent decrease after
12 hours (t2) was observed in both groups (P=0.025). However,
uNGAL values were significantly reduced in group F at t1 (P=0.02)
and t2 (P=0.04) compared with group C (*).
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zation of renal perfusion. In our study, all enrolled
patients experienced NGAL, CysC, (and pCrea) relative
increase after CPB with respect to their baseline value,
even when such increments did not reach a frankly
pathologic cut-off. Nevertheless, this increase was signif-
icantly blunted by fenoldopam. Furthermore, fewer
patients in group F experienced an increase of uNGAL
over 200 ng/ml, recently identified as a reliable cut-off
marker of renal function [35]. It is possible that in most
cases, such renal impairment would have remained
undiagnosed, considering the few patients requiring
renal replacement. In a recent large pooled analysis,
Haase and co-workers [36] confirmed that a progressive
increase in length of hospital stay is present with
increasing biomarkers levels, even in patients with
normal creatinine. However, analysis of AKI incidence
in our population surprisingly showed that 50% of
patients in group F and more than 70% in group P were
classified in one of the pRIFLE classes.
Adequate systemic DO2 during CPB may be one of
the most important determinants of “optimal” perfusion,
and it has been shown to be an independent risk factor
for cardiac surgery-associated AKI [10]. In a cohort of
1,048 coronary artery bypass graft (CABG) patients,
Ranucci et al. [10] evidenced that an indexed DO2 of
272 ml/min/m
2 was a critical value for development for
postoperative renal dysfunction in a large cohort of
adult patients. During our study, only 8% of patients in
group F (vs. 27% in group P) reached such a critical
level of indexed DO2. It must be remarked that it is cur-
rently unknown whether such results might be applic-
able to the pediatric setting. However, during pediatric
CPB, management of vascular resistances plays a key
role to deliver adequate and homogeneous whole-body
DO2, so a variety of vasodilator agents have been stu-
died for their effects on tissue perfusion during CPB.
Phentolamine is a nonselective competitive alpha1 and
alpha2 catecholamine-receptor blocker. It has a half-life
of 19 minutes, and it is eliminated mainly by the kid-
neys. Through postsynaptic receptor inhibition, it has a
vasodilating and hypotensive effect that can improve
cardiovascular parameters during CPB [17]. More
recently, fenoldopam has been used during adult cardiac
surgery. The association between its vasodilating propri-
eties with its specificity on renal (and splanchnic) perfu-
sion makes it a potentially ideal agent during pediatric
CPB. Interestingly, in a recent RCT on adult cardiac
surgery, patients were randomly assigned to receive the
Figure 3 Urinary cystatin-C (uCysC) levels. A significant increase
of uCysC levels from baseline to ICU admission and a subsequent
decrease after 12 hours was observed in both groups (P=0.039).
UCysC values were significantly reduced at t1 (P=0.04) in group F
with respect to group C (*).
Table 4 Average (standard deviation) levels found
T0 T1 T2 P
Group F Group P Group F Group P Group F Group P
MAP (mm Hg) 53.1 (8.6) 54.6 (10.7) 62.9 (10.9) 64.6 (14.0) 65.7 (13.0) 62.5 (11.2) 0.99
IS 0 (0) 0 (0) 9.5 (5) 12.7 (9) 8.7 (5) 9.1 (6) 0.374
Lactates (mM) 1.0 (0.5) 0.9 (0.5) 3.3 (2.4) 3.8 (2.5) 1.6 (1.0) 1.9 (1.5) 0.433
ScvO2 (%) 59.6 (16.6) 59.8 (17.3) 58.1 (15.0) 59.0 (15.3) 61.9 (16.0) 56.7 (14.8) 0.555
rSO2c (%) 58.0 (12.1) 58.6 (10.9) 59.8 (15.3) 56.9 (14.7) 64.0 (9.3) 63.5 (11.3) 0.590
Diuresis (ml/kg/h) 5.9 (5.2) 6.9 (6.3) 7.5 (6.7) 6.8 (4.7) 5.0 (2.5) 4.7 (2.8) 0.340
CPB phase
Group F Group P
CPB press
a (mm Hg) 47.2 (4.7) 49.0 (4.6) 0.048
Effective CPB flow
a (ml/kg/min) 151 (12.5) 146.5 (16) 0.142
IDO2
a
(ml O2/min/m
2)
342.4 (50.1) 331.7 (58.7) 0.460
ISVR
a (dyn·s·cm
-5/m
2) 404.9 (59.8) 423.5 (97.2) 0.502
Levels of mean arterial pressure (MAP), lactates, central venous saturation (ScvO2), cerebral near infrared spectroscopy (rSO2c), urine output, cardiopulmonary
bypass (CPB) pressure, indexed oxygen delivery (IDO2), and indexed systemic vascular resistances (ISVR) collected before surgery (t0), at the end of the surgical
procedure (t1) and 12 hours after intensive care unit admission (t2). Diuresis at t1 includes intraoperative urine output.
aData collected exclusively during CPB
phase. Data are expressed as mean (standard deviation).
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cebo [37]. Fenoldopam infusion started at the onset of
CPB and was maintained for the first 12 postoperative
hours. Patients in the fenoldopam group had higher
DO2 during CPB, higher pump flow rate, and a signifi-
cantly lower perfusion pressure, although this parameter
was still within the normal range. Blood lactate concen-
trations during CPB were similar in the two groups.
Urine output during and after CPB did not differ
between groups, nor did the renal function parameters.
A significantly higher rate of AKI was found in the pla-
cebo group (10% vs. 0) [37].
In our study, during CPB, we administered 0.1 mg/kg
phentolamine boluses in case of high perfusion pressure
at full perfusion flow. Similar to the Ranucci et al.t r i a l
[37], average DO2 levels, SVR, ScvO2,r S O 2c, and blood
lactates suggested adequate perfusion in both groups.
However, in the fenoldopam group, CPB average perfu-
sion pressure was significantly lower, and the average
effective CPB flow tended to be higher (even higher
than the prescribed flow of 150 ml/kg/min). We specu-
late that a continuous fenoldopam infusion warranted a
constant systemic vasodilatation and a better overall
perfusion than did repeated phentolamine boluses. This
assumption may be supported by the renal biomarker
difference, and by the fact that patients in group F
required a lower amount of phentolamine and furose-
mide administration: this effect might be explained,
again, by the optimization of renal (and splanchnic) per-
fusion during CPB. It must be remarked, however, that
these speculations derive from an associative analysis,
because phentolamine/furosemide administration was
not limited by study protocol. This trial had several
strengths and pitfalls. This was the first RCT examining
the use of high-dose fenoldopam during CPB in pedia-
tric surgery. The trial was stratified by age and included
an homogeneous cohort of young babies who might
have different CPB physiopathology and systemic vascu-
lar resistances from those of older children. The limits
of this trial were that it was a single-center study, limit-
ing its external validity; it was not powered for post-
operative pediatric AKI; a cost/benefit analysis was not
performed; palliative surgery, DHCA procedures, and
RACHS 5 and 6 were excluded by protocol from enrol-
ment, whereas in these kinds of patients, the impact of
perfusion optimization on organ protection would have
been potentially magnified; finally, only indices of renal
function were strictly monitored and eventually consid-
ered as surrogates of splanchnic perfusion. However, it
must be remarked that this was an initial experience,
and the potential feasibility of high-dose fenoldopam
during pediatric CPB has not been evaluated before;
therefore, a sensitive and specific biomarker of renal
ischemic injury was targeted as the primary objective
instead of cardiac surgery-associated AKI or other
organs dysfunction, due to the specific fenoldopam
action on renal perfusion: this primary outcome allowed
us to reduce sample size and costs of the trial; further-
more, the administration of the drug was limited to a
“safer” cohort of CHD, at lower risk of perioperative
morbidity and unstable hemodynamics. After such
results, the extended application of high-dose fenoldo-
pam to patients with univentricular anatomy and higher
RACHS score is currently under evaluation in our
institution.
Conclusions
In conclusion, high-dose fenoldopam during CPB in
pediatric cardiac surgery appeared to be safe and poten-
tially nephroprotective. The routine prophylactic use of
this agent during CPB cannot be recommended on the
basis of this trial, especially before an accurate cost/ben-
efit analysis is performed; however, our data encourage
further research in this field.
Key messages
￿ Cardiopulmonary bypass during pediatric cardiac
surgery induces a significant increase of urinary and
plasmatic NGAL and CysC levels from baseline to
ICU admission followed by restoration of normal
values after 12 hours.
￿ Urinary NGAL and CysC increase is significantly
r e d u c e da tt h ee n do fs u r g e r ya n d1 2h o u r sa f t e r
ICU admission by the infusion of 1 μg/kg/min of
fenoldopam.
￿ Fenoldopam infusion may improve systemic vaso-
dilation and renal perfusion during CPB: compared
with controls, a significant reduction in furosemide
and phentolamine requirement during CPB was
observed in patients receiving fenoldopam.
￿ AKI incidence, as indicated by pRIFLE classifica-
tion after pediatric cardiac surgery, is high. Accord-
ing to our data, it was 50% in patients receiving
fenoldopam and 72% in controls.
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